A Literature Systematic Review with Meta-Analysis of Symptoms Prevalence in Covid-19: the Relevance of Olfactory Symptoms in Infection Not Requiring Hospitalization

Abstract

Purpose of review To investigate the association between the olfactory dysfunction and the more typical symptoms (fever, cough, dyspnoea) within the Sars-CoV-2 infection (COVID-19) in hospitalized and non-hospitalized patients. Recent findings PubMed, Scopus and Web of Science databases were reviewed from May 5, 2020, to June 1, 2020. Inclusion criteria included English, French, German, Spanish or Italian language studies containing original data related to COVID19, anosmia, fever, cough, and dyspnoea, in both hospital and non-hospital settings. Two investigators independently reviewed all manuscripts and performed quality assessment and quantitative meta-analysis using validated tools. A third author arbitrated full-text disagreements. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), 11 of 135 studies fulfilled eligibility. Anosmia was estimated less prevalent than fever and cough (respectively rate difference = − 0.316, 95% CI: − 0.574 to − 0.058, Z = − 2.404, p G 0.016, k = 11 and rate difference = − 0.249, 95% CI: − 0.402 to − 0.096, Z = − 3.185, p G 0.001, k = 11); the analysis between anosmia and dyspnoea was not significant (rate difference = − 0.008, 95% CI: − 0.166 to 0.150, Z = − 0.099, p G 0.921, k = 8). The typical symptoms were significantly more frequent than anosmia in hospitalized more critical patients than in non-hospitalized ones (respectively [Q(1) = 50.638 p G 0.000, Q(1) = 52.520 p G 0.000, Q(1) = 100.734 p G 0.000). Summary Patient with new onset olfactory dysfunction should be investigated for COVID-19. Anosmia is more frequent in non-hospitalized COVID-19 patients than in hospitalized ones.

Neurological Manifestations as the Predictors of Severity and Mortality in Hospitalized Individuals with COVID-19: A Multicenter Prospective Clinical Study

“…The study design, sample size, recruitment setting (inpatients vs. outpatients), and model of testing smell sensation (self-reporting survey vs. physical exam) could signi cantly affect the results. It was found that anosmia was more common in non-hospitalized individuals than hospitalized ones with COVID-19 (39,40). Our study showed that loss of smell and taste was associated with reduced odds of severe cases and death due among hospitalized cases.…”

Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis

“…This result was almost thrice the initial prevalence reported from Wuhan, China 174 , 208 . This suggests that anosmia is a potential indicator of SARS-CoV-2 infection, and may be useful for screening and early identification of COIVD-19 patients, particularly asymptomatics 241 . Some countries, such as the UK and US have used anosmia as an indicator for preventive measure, wherein COVID-19 patient with anosmia should commence self-isolation 242 - 244 .…”

Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence

“…COVID-19 symptoms are highly variable, although the most commonly reported include fever, cough, fatigue, breathing difficulties, and loss of smell and taste. 3 While many individuals report mild symptoms 1 to 14 days after viral exposure, unfortunately a large portion of the affected population develops acute respiratory distress syndrome (ARDS). 4 If not treated promptly and efficiently, ARDS can dramatically turn into cytokine storms, 5 multiorgan failure, 6 septic shock, 7 and blood clots.…”